Artwork

Content provided by Mises Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mises Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Why Are US Drug Prices So High?

52:15
 
Share
 

Manage episode 483742756 series 3331717
Content provided by Mises Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mises Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Economist Alex Tabarrok joins Bob to review Trump’s executive order on prescription drug pricing. They explore how price discrimination works in global pharmaceutical markets, the unintended consequences of importation policies, and why U.S. consumers often pay more—yet benefit most from drug innovation. Tabarrok also critiques the FDA’s role in delaying treatments and explains how regulatory reform, not price caps, could make healthcare more affordable and effective. Alex's Article, "Econ 101 is Underrated: Pharma Price Controls": https://Mises.org/HAP500a
  continue reading

5971 episodes

Artwork

Why Are US Drug Prices So High?

Mises Institute

0-10 subscribers

published

iconShare
 
Manage episode 483742756 series 3331717
Content provided by Mises Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mises Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Economist Alex Tabarrok joins Bob to review Trump’s executive order on prescription drug pricing. They explore how price discrimination works in global pharmaceutical markets, the unintended consequences of importation policies, and why U.S. consumers often pay more—yet benefit most from drug innovation. Tabarrok also critiques the FDA’s role in delaying treatments and explains how regulatory reform, not price caps, could make healthcare more affordable and effective. Alex's Article, "Econ 101 is Underrated: Pharma Price Controls": https://Mises.org/HAP500a
  continue reading

5971 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play